Clinical Trial Update: Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma [Phase 2]

View source ↗

Summary

Phase II study updating on adding DCVAC/OvCa to first-line carboplatin and paclitaxel for newly diagnosed epithelial ovarian cancer (Phase 2; completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Ovarian Neoplasms

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DCVAC/OvCa
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: SOTIO a.s. | Conditions: Ovarian Neoplasms, Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED